TAK vs ZBH
Takeda Pharmaceutical Company Limited vs Zimmer Biomet — AI-powered side-by-side comparison
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
VS
| Metric | TAK | ZBH |
|---|
| AI Score |
67
|
69
|
| Price |
$17.49
|
$97.22
|
| P/E Ratio |
48.87×
|
23.54×
|
| ROE |
2.6%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.1%
|
69.9%
|
| Debt / Equity |
0.65×
|
0.59×
|
| Dividend Yield |
3.6%
|
1.0%
|
| RSI (14) |
61.6
|
63.1
|
| Beta |
0.088
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for TAK versus ZBH.
ZBH leads by 2 points.
ZBH scores 69/100 (Buy) versus TAK at 67/100 (Insufficient Data).
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical